Status of FAS and FAS Ligand Gene Polymorphisms in Patients wi th Breast Cancer in Northeastern IRAN

Publish Year: 1397
نوع سند: مقاله ژورنالی
زبان: English
View: 295

This Paper With 7 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

این Paper در بخشهای موضوعی زیر دسته بندی شده است:

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_RBMB-7-1_004

تاریخ نمایه سازی: 22 دی 1399

Abstract:

Background: The First apoptosis signal (FAS) and First apoptosis signal ligand (FASL) genes initiate the apoptosis pathway, playing a central role in the tumor growth and metastasis. Gene polymorphisms including -1377 G/A in the promoter region of FAS and -844 C/T in the promoter region of FASL have shown to change the transcription activities of these genes. Methods: In this study we evaluated association of these polymorphisms with risk of metastasis of breast cancer, in a population selected from Mashhad, Iran. A total of 115 patients with breast cancer and 115 controls were recruited in this case-control study. Polymerase Chain Reaction-based Restriction Fragment Length Polymorphism (PCR-RFLP) was applied for genotyping on extracted DNA from participant’s blood. Unconditional logistic regression was used to estimate cancer risk by calculating odds ratios (OR) and their 95% confidence intervals (95% CIs). Results: There was no significant association between these genetic polymorphisms and breast cancer risk. Additionally, our results showed no significant influence from the above mentioned gene polymorphisms on metastasis of breast cancer. Conclusions: These results suggest that the FAS-1377G/A and FASL-844 C/T gene polymorphism don’t have much influence on the susceptibility to metastasis of breast cancer in northeastern Iranian population. Therefore, we suggest to investigate impact of other candidate gene polymorphisms on metastasis of breast cancer for future research.

Authors

Seyed Amir Jalali

Department of Immunology, Medical School, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Fatemeh Homaei Shandiz

Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Jalil Tavakol Afshari

Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran & Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Maryam Davarpanah Tanha Ghochan

Physiology Research Center, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.

Amin Reza Nikpoor

Immunology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran & Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Mojgan Mohammadi

Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran & Allergy Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.